Abstract
Chemoprevention has been widely explored as a promising strategy for controlling the incidence of lung cancer, the leading cause of cancer-related death. To maximize the benefit of lung cancer chemoprevention, it is important to identify individuals at high risk for the disease. The genetic background has been shown to play an important role in one's risk of developing lung cancer. We report here the identification of a polymorphic tandem repeats minisatellite (termed MNS16A) in the downstream region of the human telomerase gene. This minisatellite is located upstream of an antisense transcript from the human telomerase gene locus and was demonstrated to have promoter activity. The promoter activity was significantly lower in the construct containing the shorter repeats, suggesting that the MNS16A variant may have a relevance of functionality. To explore the role of this novel polymorphism in lung cancer, we conducted a pilot hospital-based case–control study by identifying the MNS16A genotype with genomic DNA from 53 lung cancer patients and 72 cancer-free controls. We found four different alleles and classified them as shorter (S) or longer (L) on the functional basis of the length of the repeats in the controls. The MNS16A genotype distributions of the SS, SL, and LL genotypes were 11, 32, and 57%, respectively, in the cases, and 14, 40, and 46%, respectively, in the controls. Compared with the SS+SL genotype, the LL genotype was associated with greater than twofold increased risk of lung cancer (odds ratio=2.18; 95% confidence interval=0.92, 5.20) after adjustment for age, sex, ethnicity, and smoking status, suggesting a potential role of MNS16A in lung cancer susceptibility. Larger studies are needed to verify our findings.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Albanell J, Lonardo F, Rusch V, Engelhardt M, Langenfeld J, Han W, Klimstra D, Venkatraman E, Moore MA and Dmitrovsky E . (1997). J. Natl. Cancer Inst., 89, 1609–1615.
Bouchardy C, Benhamou S, Jourenkova N, Dayer P and Hirvonen A . (2001). Lung Cancer, 32, 109–112.
Bryce LA, Morrison N, Hoare SF, Muir S and Keith WN . (2000). Neoplasia, 2, 197–201.
Dhaene K, Van Marck E and Parwaresch R . (2000). Virchows Arch., 437, 1–16.
Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, Adams RR, Chang E, Allsopp RC, Yu J, Le S, West MD, Harley CB, Andrews WH, Greider CW and Villeponteau B . (1995). Science, 269, 1236–1241.
Greider CW and Blackburn EH . (1985). Cell, 43, 405–413.
Goode EL, Ulrich CM and Potter JD . (2002). Cancer Epidemiol. Biomarkers Prev., 11, 1513–1530.
Hiyama K, Hiyama E, Ishioka S, Yamakido M, Inai K, Gazdar AF, Piatyszek MA and Shay JW . (1995). J. Natl. Cancer Inst., 87, 895–902.
Hoff-Olsen P, Meling GI and Olaisen B . (1995). Hum. Mutat., 5, 329–332.
Honma M, Mizusawa H, Sasaki K, Hayashi M, Ohno T, Tanaka N and Sofuni T . (1994). Mutat. Res., 304, 167–179.
Imai H, Nakagama H, Komatsu K, Shiraishi T, Fukuda H, Sugimura T and Nagao M . (1997). Proc. Natl. Acad. Sci. USA, 94, 10817–10820.
Jeffreys AJ, Tamaki K, MacLeod A, Monckton DG, Neil DL and Armour JA . (1994). Nat. Genet., 6, 136–145.
Jeffreys AJ, Wilson V, Kelly R, Taylor BA and Bulfield G . (1987). Nucleic Acids Res., 15, 2823–2836.
American Cancer Society Inc. (2003). Cancer facts & figures, American Cancer Society: Atlanta, GA. pp. 2–5.
Kaplanski C, Srivatanakul P and Wild CP . (1997). Int. J. Cancer, 72, 248–254.
Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, Coviello GM, Wright WE, Weinrich SL and Shay JW . (1994). Science, 266, 2011–2015.
Ledwith BJ, Storer RD, Prahalada S, Manam S, Leander KR, van Zwieten MJ, Nichols WW and Bradley MO . (1990). Cancer Res., 50, 5245–5249.
Ledwith BJ, Joslyn DJ, Troilo P, Leander KR, Clair JH, Soper KA, Manam S, Prahalada S, van Zwieten MJ and Nichols WW . (1995). Carcinogenesis, 16, 1167–1172.
Leem S-H, Londoňo-Vallejo JA, Kim J-H, Bui H, Tubacher E, Solomon G, Park J-E, Horikawa I, Kouprina N, Barrett JC and Larionov V . (2002). Oncogene, 21, 769–777.
Matsumura Y and Tarin D . (1992). Cancer Res., 52, 2174–2179.
Meyerson M, Counter CM, Eaton EN, Ellisen LW, Steiner P, Caddle SD, Ziaugra L, Beijersbergen RL, Davidoff MJ, Liu Q, Bacchetti S, Haber DA and Weinberg RA . (1997). Cell, 90, 785–795.
Murnane JP, Sabatier L, Marder BA and Morgan WF . (1994). EMBO J., 13, 4953–4962.
Nakamura TM, Morin GB, Chapman KB, Weinrich SL, Andrews WH, Lingner J, Harley CB and Cech TR . (1997). Science, 277, 955–959.
Paquette B and Little JB . (1992). Cancer Res., 52, 5788–5793.
Parkin DM, Pisani P and Ferlay J . (1999). CA Cancer J. Clin., 49, 33–64.
Shen H, Wang L, Spitz MR, Hong WK, Mao L and Wei QY . (2002). Cancer Res., 62, 4992–4995.
Soria JC, Moon C, Wang L, Hittelman WN, Jang SJ, Sun S-Y, Lee JJ, Liu D, Kurie JM, Morice RC, Lee JS, Hong WK and Mao L . (2001). J. Natl. Cancer Inst., 93, 1257–1263.
Spitz MR, Wu X, Wang Y, Wang LE, Shete S, Amos CI, Quo Z, Lei L, Mohrenweiser H and Wei Q . (2001). Cancer Res., 61, 1354–1357.
Szutorisz H, Palmqvist R, Roos G, Stenling R, Schorderet DF, Reddel R, Lingner J and Nabholz M . (2001). Oncogene, 20, 2600–2605.
Thein SL, Jeffreys AJ, Gooi HC, Cotter F, Flint J, O'Connor NT, Weatherall DJ and Wainscoat JS . (1987). Br. J. Cancer, 55, 353–356.
Wang L, Soria JC, Kemp BL, Liu DD, Mao L and Khuri FR . (2002). Clin. Cancer Res., 8, 2883–2889.
Wei Q, Cheng L, Amos CI, Wang LE, Guo Z, Hong WK and Spitz MR . (2000). J. Natl. Cancer Inst., 92, 1764–1772.
Wick M, Zubov D and Hagen G . (1999). Gene, 232, 97–106.
Xiong Y and Eickbush TH . (1990). EMBO J., 9, 3353–3362.
Yashima K, Litzky LA, Kaiser L, Rogers T, Lam S, Wistuba II, Milchgrub S, Srivastava S, Piatyszek MA, Shay JW and Gazdar AF . (1997). Cancer Res., 57, 2373–2377.
Acknowledgements
This work was supported in part by Grant DAMD17-01-1-0689-1 from the Department of Defense and Grants PO1 CA91844, P30 CA16620, and U01 CA 86390 from the National Cancer Institute, USA. We thank Stephanis Deming for editing the manuscript and patient population identified through a search of the tumor registry database maintained by the Department of Medical Informatics.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wang, L., Soria, JC., Chang, YS. et al. Association of a functional tandem repeats in the downstream of human telomerase gene and lung cancer. Oncogene 22, 7123–7129 (2003). https://doi.org/10.1038/sj.onc.1206852
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1206852
Keywords
This article is cited by
-
Association between hTERT polymorphisms and the risk of breast cancer in a sample of Southeast Iranian population
BMC Research Notes (2014)
-
The MNS16A polymorphism in the TERT gene in peri-centenarians from the Han Chinese population
Science China Life Sciences (2014)
-
HTERT MNS16A polymorphism in breast cancer: a case–control study
Molecular Biology Reports (2012)
-
A functional tandem-repeats polymorphism in the downstream of TERTis associated with the risk of nasopharyngeal carcinoma in Chinese population
BMC Medicine (2011)
-
Association of telomerase gene hTERT polymorphism and malignant gliomas
Journal of Neuro-Oncology (2007)